Since our tumor model of HER2 overexpression and HACE1 loss is driven by Rac1 hyperactivation, we evaluated the antitumor activity of EHT1864 in orthotopic-implanted MCF12A-HER2 shHACE1 cells. Here, RAC1 is linked to neoplasm.